Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium Tuberculosis Complex Strains

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2016 Apr 8

PMID 27053671

Citations 20

Authors

Florence Brossier

David Guindo

Anne Pham

Florence Reibel

Wladimir Sougakoff

Nicolas Veziris

Alexandra Aubry

Affiliations

Soon will be listed here.

Abstract

Detecting resistance to fluoroquinolones (FQ) and second-line injectable drugs (amikacin [AMK], kanamycin [KAN], and capreomycin [CAP]) is crucial given the worldwide increase in the incidence of extensively drug-resistant tuberculosis (XDR-TB). A new version of the GenoType MTBDRsl test (v2.0) has been developed to improve the detection of resistance to FQ (involving gyrA and gyrB mutations) and to second-line injectable drugs (involving rrs and eis promoter mutations) in Mycobacterium tuberculosis A collection of 127 multidrug-resistant (MDR) M. tuberculosis complex strains was tested using the first (v1) and second (v2.0) versions of the MTBDRsl test, as well as DNA sequencing. The specificities in resistance detection of v1 and v2.0 were similar throughout, whereas the levels of sensitivity of v2.0 were superior for FQ (94.8% versus 89.6%) and KAN (90.5% versus 59.5%) but similar for AMK (91.3%) and CAP (83.0%). The sensitivity and specificity of v2.0 were superior to those of v1 for the detection of pre-XDR strains (83.3% versus 75.0% and 88.6% versus 67.1%, respectively), whereas the sensitivity of v2.0 was superior to that of v1 only for the detection of XDR strains (83.0% versus 49.1%). In conclusion, MTBDRsl v2.0 is superior to MTBDRsl v1 and efficiently detects the most common mutations involved in resistance to FQ and aminoglycosides/CAP. However, due to mutations not recognized by v2.0 or to the presence of resistance mechanisms not yet characterized (particularly mechanisms related to monoresistance to aminoglycosides or CAP), the results for wild-type strains obtained with MTBDRsl v2.0 should be confirmed by further DNA sequencing and phenotypic drug susceptibility testing.

Citing Articles

In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.

Brankin A, Seifert M, Georghiou S, Walker T, Uplekar S, Suresh A Sci Rep. 2022; 12(1):17741.

PMID: 36273016 PMC: 9587982. DOI: 10.1038/s41598-022-21025-6.

Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study.

Diriba G, Alemu A, Tola H, Yenew B, Amare M, Eshetu K IJID Reg. 2022; 5:39-43.

PMID: 36176268 PMC: 9513164. DOI: 10.1016/j.ijregi.2022.08.012.

Utility of line probe assay in detecting drug resistance and the associated mutations in patients with extrapulmonary tuberculosis in Addis Ababa, Ethiopia.

Diriba G, Kebede A, Tola H, Alemu A, Yenew B, Moga S SAGE Open Med. 2022; 10:20503121221098241.

PMID: 35646363 PMC: 9130810. DOI: 10.1177/20503121221098241.

A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Complex Directly From Clinical Samples.

Bonnet I, Enouf V, Morel F, Ok V, Jaffre J, Jarlier V Front Cell Infect Microbiol. 2021; 11:707244.

PMID: 34778100 PMC: 8586210. DOI: 10.3389/fcimb.2021.707244.

Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.

Singh K, Kumari R, Gupta S, Tripathi R, Srivastava A, Shakya V Ann Clin Microbiol Antimicrob. 2021; 20(1):56.

PMID: 34446022 PMC: 8394194. DOI: 10.1186/s12941-021-00463-6.

References

Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G . First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS One. 2014; 9(4):e95083. PMC: 3990612. DOI: 10.1371/journal.pone.0095083. View

Maus C, Plikaytis B, Shinnick T . Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005; 49(2):571-7. PMC: 547314. DOI: 10.1128/AAC.49.2.571-577.2005. View

CANETTI G, RIST N, Grosset J . [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris). 1963; 27:217-72. View

Chakravorty S, Lee J, Cho E, Roh S, Smith L, Lee J . Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen.... J Clin Microbiol. 2014; 53(1):43-51. PMC: 4290905. DOI: 10.1128/JCM.02059-14. View

Gikalo M, Nosova E, Krylova L, Moroz A . The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2012; 67(9):2107-9. DOI: 10.1093/jac/dks178. View

Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N . Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother. 2013; 57(9):4496-500. PMC: 3754299. DOI: 10.1128/AAC.00506-13. View

Georghiou S, Magana M, Garfein R, Catanzaro D, Catanzaro A, Rodwell T . Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One. 2012; 7(3):e33275. PMC: 3315572. DOI: 10.1371/journal.pone.0033275. View

Zaunbrecher M, Sikes Jr R, Metchock B, Shinnick T, Posey J . Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2009; 106(47):20004-9. PMC: 2785282. DOI: 10.1073/pnas.0907925106. View

Camus J, Pryor M, Medigue C, Cole S . Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology (Reading). 2002; 148(Pt 10):2967-2973. DOI: 10.1099/00221287-148-10-2967. View

10.

Kliiman K, Altraja A . Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009; 33(5):1085-94. DOI: 10.1183/09031936.00155708. View

11.

Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W . Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2010; 48(5):1683-9. PMC: 2863904. DOI: 10.1128/JCM.01947-09. View

12.

Maruri F, Sterling T, Kaiga A, Blackman A, van der Heijden Y, Mayer C . A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012; 67(4):819-31. PMC: 3299416. DOI: 10.1093/jac/dkr566. View

13.

Maus C, Plikaytis B, Shinnick T . Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005; 49(8):3192-7. PMC: 1196259. DOI: 10.1128/AAC.49.8.3192-3197.2005. View

14.

Engstrom A, Perskvist N, Werngren J, Hoffner S, Jureen P . Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2011; 66(6):1247-54. DOI: 10.1093/jac/dkr109. View

15.

Van Deun A, Aung K, Bola V, Lebeke R, Hossain M, De Rijk W . Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013; 51(8):2633-40. PMC: 3719626. DOI: 10.1128/JCM.00553-13. View

16.

Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A . Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2015; 59(8):4800-8. PMC: 4505224. DOI: 10.1128/AAC.00150-15. View

17.

Malik S, Willby M, Sikes D, Tsodikov O, Posey J . New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012; 7(6):e39754. PMC: 3386181. DOI: 10.1371/journal.pone.0039754. View

18.

Du Q, Dai G, Long Q, Yu X, Dong L, Huang H . Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China. Diagn Microbiol Infect Dis. 2013; 77(2):138-42. DOI: 10.1016/j.diagmicrobio.2013.06.031. View

19.

Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V . Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother. 2012; 56(4):1990-6. PMC: 3318379. DOI: 10.1128/AAC.06272-11. View

20.

Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F . Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother. 2009; 53(10):4498-500. PMC: 2764174. DOI: 10.1128/AAC.00287-09. View